Cyclerion Therapeutics, Inc. financial data

Symbol
CYCN on Nasdaq
Location
301 Binney Street, Cambridge, MA
State of incorporation
MA
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 4, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 446 % +126%
Return On Equity -34.2 % +46%
Return On Assets -30.7 % +27%
Operating Margin -172 % +94.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 2.71M shares 0%
Common Stock, Shares, Outstanding 2.55M shares +2.9%
Entity Public Float 4.8M USD -32.4%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 2.52M shares +7.7%
Weighted Average Number of Shares Outstanding, Diluted 2.52M shares +7.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 194K USD
Research and Development Expense 286K USD -81.1%
General and Administrative Expense 5.34M USD -34.3%
Operating Income (Loss) -3.63M USD +72%
Nonoperating Income (Expense) 571K USD +59.5%
Net Income (Loss) Attributable to Parent -3.06M USD +41.9%
Earnings Per Share, Basic -1.21 USD/shares +46.2%
Earnings Per Share, Diluted -1.21 USD/shares +46.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.23M USD -57.3%
Accounts Receivable, after Allowance for Credit Loss, Current 556K USD
Other Assets, Current 16K USD +45.5%
Assets, Current 4.23M USD -47.3%
Other Long-term Investments 5.35M USD 0%
Property, Plant and Equipment, Net 0 USD
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 9.58M USD -28.4%
Accounts Payable, Current 390K USD -67.4%
Liabilities, Current 725K USD -65.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -267M USD -1.16%
Stockholders' Equity Attributable to Parent 8.85M USD -21.6%
Liabilities and Equity 9.58M USD -28.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.87M USD +69.9%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 2.71M shares +2.46%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.88M USD +69.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.23M USD -57.3%
Deferred Tax Assets, Valuation Allowance 83.2M USD +0.87%
Deferred Tax Assets, Gross 83.2M USD +0.87%
Property, Plant and Equipment, Gross 126K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 53.3M USD +9.78%
Preferred Stock, Shares Authorized 100M shares 0%
Unrecognized Tax Benefits 0 USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 625K USD -41.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares